CorMedix (CRMD) Q3 2024 earnings summary

Executive summary

• Achieved $11.5 million in net revenue for Q3 2024, marking the first full quarter of DefenCath sales following its outpatient launch in July 2024 and inpatient launch in April 2024.

• Signed agreements with two mid-size and one large dialysis operator, expanding access to 60% of U.S. outpatient dialysis clinics.

• Outpatient adoption is protocol-driven with rapid patient conversion, while inpatient uptake is progressing more slowly due to complex hospital protocols.

• US Renal Care accounted for over 90% of Q3 sales, with efforts underway to diversify the customer base.

• DefenCath is the first and only FDA-approved antimicrobial catheter lock solution in the U.S., with exclusivity through 2033 and potential patent protection through 2042.

Financial highlights

• Q3 2024 net revenue: $11.5 million; nine-month 2024 net revenue: $12.3 million; Q3 net loss: $2.8 million ($0.05/share), a significant improvement from $9.7 million ($0.17/share) in Q3 2023.

• Gross profit for Q3 2024 was $10.8 million, with gross margin over 90% due to minimal cost of sales from previously expensed inventory.

• Operating expenses rose 33–34% to $14.1 million, mainly from higher selling, marketing, and G&A costs, offset by lower R&D.

• Cash, cash equivalents, and short-term investments totaled $46.0 million as of September 30, 2024, down from $76.0 million at year-end 2023.

• Net cash used in operations for the first nine months: $45.0 million, up from $27.7 million in 2023.

Outlook and guidance

• Management expects to be EBITDA positive in Q4 2024, with operating expenses for Q4 projected in the $15–17 million range.

• Sufficient cash and inventory to fund operations for at least twelve months from the report date; no significant impact anticipated from transition to ASP-based reimbursement in early 2025.

• Plans include expanding DefenCath indications, launching an Expanded Access Program by year-end, and starting new clinical studies in early 2025.